Tag - FIXX

Markets

Stifel starts coverage on 10 rare disease-focused companies

Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...

March 1, 2021

Developments

Homology’s PKU gene therapy gets FDA fast track designation

Homology Medicines’ (NASDAQ:FIXX) received FDA fast track designation for HMI-102, a gene therapy for the treatment of adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU...

May 14, 2019

Developments

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

Homology Medicines (NASDAQ:FIXX) received FDA clearance to commence its Phase 1/2 study of HMI-102 in adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU lack the...

April 5, 2019

Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018

Tag - FIXX

Stifel starts coverage on 10 rare disease-focused companies

Homology’s PKU gene therapy gets FDA fast track designation

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

BTIG starts Homology Medicines at buy; PT $35

General

More